| Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy. | |
| | |
MedLine Citation:
|
PMID: 20795850 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Diabetes mellitus has reached epidemic proportions worldwide, eliciting extensive research on both the disease process and its treatment. Regardless of diabetes type, the progressive nature of the disease makes insulin the long-term mainstay of diabetes management. Recently, the insulin analog glargine was reported in several epidemiologic studies to be associated with an increased risk of cancer. Inconsistent study results and media attention have caused much angst and concern to health care professionals and the general population. A clear understanding of the current evidence is needed to adequately develop a patient-oriented risk:benefit assessment. Members of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy evaluated available evidence to provide guidance and discussion on the risk of cancer with insulin glargine use. We believe the current link between insulin glargine and cancer is tenuous but merits further evaluation. An independent analysis of all available glargine clinical trial data should be performed, and a vigorous postmarketing safety study of glargine should be conducted. Until more substantial data are available, however, neither the choice of initial insulin therapy nor insulin maintenance regimens should be influenced by the current information linking insulin glargine to cancer. |
| | |
Authors:
|
Krystal L Edwards; Daniel M Riche; Jeffrey S Stroup; Jennifer D Goldman-Levine; Rosalyn S Padiyara; L Brian Cross; Michael P Kane |
Publication Detail:
|
Type: Journal Article; Practice Guideline |
Journal Detail:
|
Title: Pharmacotherapy Volume: 30 ISSN: 1875-9114 ISO Abbreviation: Pharmacotherapy Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-27 Completed Date: 2010-12-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8111305 Medline TA: Pharmacotherapy Country: United States |
Other Details:
|
Languages: eng Pagination: 955-65 Citation Subset: IM |
Affiliation:
|
Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, Texas 75216, USA. krystal.edwards@ttuhsc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Clinical Trials as Topic Diabetes Mellitus / drug therapy Diabetes Mellitus, Type 2 / complications, drug therapy Humans Hypoglycemic Agents / adverse effects*, therapeutic use Insulin / adverse effects, analogs & derivatives*, therapeutic use Meta-Analysis as Topic Neoplasms / chemically induced, epidemiology* Risk Factors Societies, Pharmaceutical United States |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents; 0/glargine; 11061-68-0/Insulin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.
Next Document: The essential research curriculum for doctor of pharmacy degree programs.